TNFRSF8 and heart disorder: In conclusion, treatment with brentuximab vedotin induced cell death in CD30-positive hiPSCs and reduced tumourigenicity of hiPSC cardiac derivatives in vivo, suggesting that this strategy may increase the safety of clinical applications of hiPSC-based cell therapy for heart disease.